Dr. Lal PathLabs Balance Sheet Health
Financial Health criteria checks 5/6
Dr. Lal PathLabs has a total shareholder equity of ₹20.4B and total debt of ₹417.0M, which brings its debt-to-equity ratio to 2%. Its total assets and total liabilities are ₹26.0B and ₹5.6B respectively. Dr. Lal PathLabs's EBIT is ₹5.2B making its interest coverage ratio -17.3. It has cash and short-term investments of ₹11.3B.
Key information
2.0%
Debt to equity ratio
₹417.00m
Debt
| Interest coverage ratio | -17.3x |
| Cash | ₹11.27b |
| Equity | ₹20.35b |
| Total liabilities | ₹5.62b |
| Total assets | ₹25.98b |
Recent financial health updates
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Recent updates
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results
Oct 26Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
Oct 24Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
Oct 06These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11Financial Position Analysis
Short Term Liabilities: LALPATHLAB's short term assets (₹13.3B) exceed its short term liabilities (₹4.6B).
Long Term Liabilities: LALPATHLAB's short term assets (₹13.3B) exceed its long term liabilities (₹999.0M).
Debt to Equity History and Analysis
Debt Level: LALPATHLAB has more cash than its total debt.
Reducing Debt: LALPATHLAB's debt to equity ratio has increased from 0% to 2% over the past 5 years.
Debt Coverage: LALPATHLAB's debt is well covered by operating cash flow (1286.7%).
Interest Coverage: LALPATHLAB earns more interest than it pays, so coverage of interest payments is not a concern.